221 related articles for article (PubMed ID: 17135223)
21. A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK.
Karnon J; Bakhai A; Brennan A; Pandor A; Flather M; Warren E; Gray D; Akehurst R
Int J Cardiol; 2006 May; 109(3):307-16. PubMed ID: 16026869
[TBL] [Abstract][Full Text] [Related]
22. Development and validation of a cardiovascular risk assessment model in patients with established coronary artery disease.
Battes L; Barendse R; Steyerberg EW; Simoons ML; Deckers JW; Nieboer D; Bertrand M; Ferrari R; Remme WJ; Fox K; Takkenberg JJ; Boersma E; Kardys I
Am J Cardiol; 2013 Jul; 112(1):27-33. PubMed ID: 23558041
[TBL] [Abstract][Full Text] [Related]
23. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
Ferrari R
Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):15-29. PubMed ID: 15723572
[TBL] [Abstract][Full Text] [Related]
24. The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial.
Henriksson M; Epstein DM; Palmer SJ; Sculpher MJ; Clayton TC; Pocock SJ; Henderson RA; Buxton MJ; Fox KA
Heart; 2008 Jun; 94(6):717-23. PubMed ID: 18032459
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of captopril therapy after myocardial infarction.
Tsevat J; Duke D; Goldman L; Pfeffer MA; Lamas GA; Soukup JR; Kuntz KM; Lee TH
J Am Coll Cardiol; 1995 Oct; 26(4):914-9. PubMed ID: 7560617
[TBL] [Abstract][Full Text] [Related]
26. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study.
Bertrand ME; Ferrari R; Remme WJ; Simoons ML; Deckers JW; Fox KM;
Am Heart J; 2010 May; 159(5):795-802. PubMed ID: 20435188
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial.
Bakhai A; Stone GW; Grines CL; Murphy SA; Githiora L; Berezin RH; Cox DA; Stuckey T; Griffin JJ; Tcheng JE; Cohen DJ;
Circulation; 2003 Dec; 108(23):2857-63. PubMed ID: 14610016
[TBL] [Abstract][Full Text] [Related]
29. [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].
Ferrari R; Papa K; Bernocchi P; Gimbatti OJ; Golcea SS; Bettini A; Ceconi C
Ital Heart J; 2005 Nov; 6 Suppl 7():24S-32S. PubMed ID: 16485514
[TBL] [Abstract][Full Text] [Related]
30. Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model.
Oemrawsingh RM; Akkerhuis KM; Van Vark LC; Redekop WK; Rudez G; Remme WJ; Bertrand ME; Fox KM; Ferrari R; Danser AH; de Maat M; Simoons ML; Brugts JJ; Boersma E;
J Am Heart Assoc; 2016 Mar; 5(3):e002688. PubMed ID: 27021566
[TBL] [Abstract][Full Text] [Related]
31. EUROPA substudies, confirmation of pathophysiological concepts. European trial on reduction of cardiac events with perindopril in stable coronary artery disease.
Simoons ML; Vos J; de Feyter PJ; Bots ML; Remme WJ; Grobbee DE; Kluft C; de Maat MP; Fox KM; Deckers JW
Eur Heart J; 1998 Sep; 19 Suppl J():J56-60. PubMed ID: 9796842
[TBL] [Abstract][Full Text] [Related]
32. The EUROPA trial.
Brophy JM
Lancet; 2003 Dec; 362(9399):1936; author reply 1936-7. PubMed ID: 14667759
[No Abstract] [Full Text] [Related]
33. Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit.
Brugts JJ; Boersma E; Simoons ML
Pharmacogenomics; 2010 Aug; 11(8):1115-26. PubMed ID: 20712529
[TBL] [Abstract][Full Text] [Related]
34. PERSUADE...(a EUROPA sub-study)...results: perindopril protects diabetic patients with coronary disease from cardiovascular death and heart attacks.
Cardiovasc J S Afr; 2004; 15(3):146. PubMed ID: 15356914
[No Abstract] [Full Text] [Related]
35. Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease - results from EUROPA.
van der Leeuw J; Oemrawsingh RM; van der Graaf Y; Brugts JJ; Deckers JW; Bertrand M; Fox K; Ferrari R; Remme WJ; Simoons ML; Boersma E; Visseren FL
Int J Cardiol; 2015 Mar; 182():194-9. PubMed ID: 25577762
[TBL] [Abstract][Full Text] [Related]
36. The EUROPA trial: design, baseline demography and status of the substudies.
Gomma AH; Fox KM
Cardiovasc Drugs Ther; 2001 Mar; 15(2):169-79. PubMed ID: 11669411
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of case-based training for primary care physicians in evidence-based medicine of patients with coronary heart disease.
Groot-Jensen S; Kiessling A; Zethraeus N; Björnstedt-Bennermo M; Henriksson P
Eur J Prev Cardiol; 2016 Mar; 23(4):420-7. PubMed ID: 25896863
[TBL] [Abstract][Full Text] [Related]
38. The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease.
Brugts JJ; de Maat MP; Boersma E; Witteman JC; van Duijn C; Uitterlinden AG; Bertrand M; Remme W; Fox K; Ferrari R; Danser AH; Simoons ML;
Cardiovasc Drugs Ther; 2009 Apr; 23(2):171-81. PubMed ID: 19082699
[TBL] [Abstract][Full Text] [Related]
39. Cost effectiveness of ramipril treatment for cardiovascular risk reduction.
Malik IS; Bhatia VK; Kooner JS
Heart; 2001 May; 85(5):539-43. PubMed ID: 11303006
[TBL] [Abstract][Full Text] [Related]
40. A review of Perindopril in the reduction of cardiovascular events.
Campbell DJ
Vasc Health Risk Manag; 2006; 2(2):117-24. PubMed ID: 17319455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
